Clinical efficacy and safety of a beta3-adrenoceptor agonist and an antimuscarinic agent in female patients with overactive overactive bladder: a randomized crossover study

Clinical efficacy and safety of a beta3-adrenoceptor agonist and an antimuscarinic agent in female patients with overactive overactive bladder: a randomized crossover study - Clinical comparison between miragegron and imidafenacin: a randomized crossover study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010060

Enrollment

100

Registered

2013-02-18

Start date

2012-01-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

Interventions

Mirabegron (50 mg daily) for 8weeks, wash out for 2 weeks and Imidafenacin (0.2 mg daily) for 8weeks Imidafenacin (0.2 mg daily) for 8weeks, wash out for 2 weeks and mirabegron (50 mg daily)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: In overactive bladder symptom score (OABSS), Q3 (urgency) score is 2 and more, and total score is 3 and more.

Exclusion criteria

Exclusion criteria: 1. Postvoid residual urine 50 mL and more, 2. Active urinary tract infection, 3. Histories of malignant tumors in the lower urinary tract, 4. Histories of surgery for the lower urinary tract in the last 3 months

Design outcomes

Primary

Measure	Time frame
Change of average urinary frequency for 24 hours	—

Secondary

Measure	Time frame
Change of average urgency frequency for 24 hours, Change of average urinary incontinence frequency for 24 hours, Change of average voided volume, Change of average nocturnal frequency, Change of QOL score, Change of flow rate, Change of post-void residual urine	—

Countries

Japan

Contacts

Public ContactKazumasa Torimoto

Nara Medical University Urology

torimoto@naramed-u.ac.jp0744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026